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AFTER MENOPAUSE, ESTROGENlevels decrease dramatically inwomen. This decrease in en-dogenous estrogen is associ-
ated with increased risk of osteoporosis
and cardiovascular disease.1-3 Decreas-
ing estrogen levels also have been hy-
pothesized to be associated with in-
creased risk of dementia. A relationship
between estrogen levels and dementia is
biologically plausible4-6 and, if present,
may have major implications for preven-
tion or delay of dementia onset. In ovari-
ectomized rats, estrogen increases cho-
line acetyltransferase activity in the basal
forebrain and hippocampus, regions
in the brain that are acetylcholine-
deficient in patients with Alzheimer dis-
ease (AD).4 In addition, estrogen im-
proves synapse formation on dendritic
spines in the hippocampus of oophorec-
tomized rats.5,7 Estrogen also may im-
prove cerebral blood flow and glucose
metabolism, and it may act as an anti-
oxidant.4,5,7,8 Another mechanism by
which estrogen may exert influence on
development of dementia is by reduc-
ing risk of cardiovascular disease.9,10 Sev-
eral population-based studies reported
lower prevalence and incidence of de-
mentia and AD in postmenopausal
women who used estrogen replace-
ment therapy, suggesting that exog-
enous estrogen use may reduce risk of
dementia.11-16 These studies, however,
have been criticized because of method-
ological limitations9,17-19; they also did not
assess endogenous estrogen. Recently, 2
studies did not find a relationship be-
tween short-term measures of endoge-
nous estrogen levels and cognitive de-
cline in healthy elderly women,20,21 but
another study did observe that higher
concentrations of bioavailable estradiol
were associated with less cognitive de-
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Context Exogenous estrogen use may lower risk of dementia in postmenopausal
women. A relationship between long-term exposure to endogenous estrogens and
incident dementia has been hypothesized but not studied.
Objective To determine whether a longer reproductive period, as an indicator of
longer exposure to endogenous estrogens, is associated with lower risk of dementia
and Alzheimer disease (AD) in women who have natural menopause.
Design and Setting The Rotterdam Study, a population-based prospective cohort
study conducted in the Netherlands.
Participants A total of 3601 women aged 55 years or older who did not have de-
mentia at baseline (1990-1993) and had information on age at menarche, age at meno-
pause, and type of menopause. Participants were reexamined in 1993-1994 and 1997-
1999 and were continuously monitored for development of dementia.
Main Outcome Measures Incidence of dementia, based on Diagnostic and Sta-
tistical Manual of Mental Disorders, Revised Third Edition criteria, and AD, based on
National Institute of Neurological Disorders and Stroke/Alzheimer’s Disease and Re-
lated Disorders Association criteria, compared by quartiles of reproductive period among
women with natural menopause.
Results During 21046 person-years of follow-up (median follow-up, 6.3 years), 199
women developed dementia, including 159 who developed AD. After adjusting for
age, dementia was not clearly associated with length of reproductive period. How-
ever, after adjusting for multiple covariates, women with natural menopause and more
reproductive years had an increased risk of dementia (adjusted rate ratio [RR] for women
with .39 reproductive years [highest quartile] compared with ,34 reproductive years
[lowest quartile], 1.78; 95% confidence interval [CI], 1.12-2.84). The adjusted RR per
year of increase was 1.04 (95% CI, 1.01-1.08). For risk of AD, the adjusted RRs were
1.51 (95% CI, 0.91-2.50) and 1.03 (95% CI, 1.00-1.07), respectively. Risk of demen-
tia associated with a longer reproductive period was most pronounced in APOE e4
carriers (adjusted RR for .39 reproductive years compared with ,34 reproductive years,
4.20 [95% CI, 1.97-8.92] for dementia and 3.42 [95% CI, 1.51-7.75] for AD), whereas
in noncarriers, no clear association with dementia or AD was observed.
Conclusion Our findings do not support the hypothesis that a longer reproductive
period reduces risk of dementia in women who have natural menopause.
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cline.22 To date, no studies have exam-
ined whether long-term exposure to en-
dogenous estrogen is related to risk of
dementia andAD.Weexaminedwhether
number of reproductive years in women
who had natural menopause was asso-
ciated with risk of developing dementia
and AD, using data from a large, popu-
lation-based, prospective cohort study.
We hypothesized that a longer repro-
ductive period, as an indirect indicator
of long-term exposure to endogenous es-
trogen, would be associated with lower
risk of dementia and AD.
METHODS
The Rotterdam Study
The Rotterdam Study is a population-
based, prospective cohort study of 3105
men and 4878 women aged 55 years or
older residing in Ommoord (including
those living in institutions), a suburb of
Rotterdam, the Netherlands, that aims
to assess the occurrence and determi-
nants of chronic diseases in later life.23
The Erasmus University Medical Eth-
ics Committee approved the study, and
written informed consent was ob-
tained from all participants. In 1990-
1993, trained research assistants vis-
ited all participants at home and
obtained information on sociodemo-
graphic characteristics, medical his-
tory, current health status, medication
use, and determinants for chronic dis-
eases. The participants were invited to
visit the research center for a clinical ex-
amination (including assessment of de-
mentia) by the research physicians. Re-
examinations took place in 1993-1994
and 1997-1999.
Analytical Sample
The present analysis is based on 3601
women who did not have dementia at
baseline and for whom data on age at
menopause, age at menarche, and type
of menopause were complete (85.4% of
the 4219 women in the Rotterdam Study
who were free of dementia at baseline).
Dementia Diagnosis
The procedures of the baseline and fol-
low-up examinations for the dementia
diagnoses have been described in de-
tail elsewhere.24,25 In a 3-step diagnos-
tic procedure, the Mini-Mental State Ex-
amination26 and the cognitive questions
from the Geriatric Mental State Sched-
ule27 were administered to all partici-
pants during the home interview. Par-
ticipants with Mini-Mental State
Examination scores of less than 26 or
Geriatric Mental State Schedule or-
ganic levels of more than 0 were in-
vited to undergo a clinical examination
by a research physician who adminis-
tered the Cambridge Examination for
Mental Disorders in the Elderly.28 Par-
ticipants in whom dementia was sus-
pected were examined by a neurologist
and tested by a neuropsychologist and,
if possible, underwent brain nuclear
magnetic resonance imaging (done in
20% of the participants diagnosed with
dementia). If the diagnostic evaluation
could not be completed, additional in-
formation was obtained from general
practitioners’ medical files. In addition
to the 3-step diagnostic procedure, par-
ticipants were continuously monitored
for development of dementia through
linkage of a general practitioners’ medi-
cal record system to the database of the
Rotterdam Study; this made it possible
to obtain follow-up diagnoses for more
than 99% of the cohort. Diagnoses of de-
mentia and AD were made by a panel
consisting of a neurologist, neuropsy-
chologist, and research physician ac-
cording to the criteria of the Diagnostic
and Statistical Manual of Mental Disor-
ders, Revised Third Edition29; diagnoses
of possible and probable AD were made
according to the National Institute of
Neurological Disorders and Stroke/
Alzheimer’s Disease and Related Disor-
ders Association criteria.30 Investiga-
tors who determined diagnoses were
blinded to all other information about
participants.
Reproductive Period
Data on age at menarche, age at meno-
pause, and type of menopause were
collected during the baseline home
interview. For the 2736 women
(76.0%) who reported a natural meno-
pause, age at menopause was defined
as the age at which menses had not
occurred for at least 1 year. Reproduc-
ibility of age at menopause was deter-
mined in 913 women who reported
age at natural menopause at baseline
as well as during the first follow-up
interview. Eighty-six percent of these
women reported ages at menopause
with a maximum deviation of ± 2
years. Forty-six percent provided the
same age at both interviews. Repro-
ductive period was defined as age at
natural menopause minus age at men-
arche. Seven hundred sixteen women
(19.9%) reported menopause occur-
ring after gynecologic surgery; 103
(2.9%) reported menopause induced
by drugs; and 46 (1.3%) reported
menopause after radiation therapy.
These women were considered as a
separate group defined as having had
artificial menopause. In 175 women,
menopause had occurred after stop-
ping oral contraceptive use. Although
these women may have had a natural
menopause, they were excluded from
the analytic sample because age at
menopause could not be verified. In
addition, 13 women who reported
highly unlikely ages at menopause (1
at age 20 years and 12 at age 60 years
or older) were excluded from the ana-
lytic sample.
Covariates
Information on educational level, smok-
ing habits, number of children from live
births, and ever use of hormone replace-
ment therapy (HRT) for menopausal
complaints was obtained during the
home interview. At the research center,
height and body weight were measured
and intake of alcohol was assessed us-
ing a food frequency questionnaire.31
Blood samples were drawn by venipunc-
ture from nonfasting participants and
apolipoproteinE(APOE)genotypingwas
performed on coded DNA samples with-
outknowledgeofdementiadiagnosis,us-
ing standard methods.32 Level of educa-
tion was dichotomized as completion of
primary education only vs higher edu-
cation. Smoking status was categorized
as current, former, or never. Use of HRT
for menopausal complaints was catego-
rized as ever vs never. (Only 82 women
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were currently using estrogen and, of
these, 49 had artificial menopause. Each
quartile of reproductive period in-
cluded 6 to 9 women taking estrogen.
Since these small numbers would not al-
ter the results, only ever vs never use was
considered.) Apolipoprotein E geno-
type was categorized as presence of at
least 1 e4 allele vs no e4 alleles.
Statistical Analyses
Data were analyzed using SAS Version
6.12(SAS Institute Inc,Cary,NC).Crude
age-specific incidence rates were calcu-
lated for women with natural meno-
pause according to quartiles of repro-
ductive years and for women with
artificial menopause. Cox proportional
hazards regression analysis was used to
assess the relationship between num-
ber of reproductive years in women with
natural menopause and risk of demen-
tia and AD. Reproductive years were in-
cluded in the model as a continuous vari-
able and as dummy variables using
quartiles. A fifth category was made for
women with artificial menopause. The
lowest quartile of reproductive years was
used as the reference group in the analy-
ses. Age was used as the time scale in the
proportional hazards models.33 Entry
time was defined as age at study entry.
Censoring age was defined as age at end
of study, death, or onset of dementia,
whichever came first. Age at onset of de-
mentia was determined as the midpoint
between the age of the participant when
last known to be at risk for dementia and
age at diagnosis (either through screen-
ing or through general practitioner
records). All models were fully ad-
justed for age (time scale), level of edu-
cation, smoking status, alcohol intake,
body mass index (BMI), use of HRT,
number of children, and APOE geno-
type. If data were missing on categori-
cal variables, an extra category was
added, whereas if data were missing on
continuous variables, the mean value of
the respective variable was imputed as
calculated from all women in the Rot-
terdam Study who did not have demen-
tia at baseline. Data were missing on edu-
cation (n=7), alcohol intake (n=669),
BMI (n=192), HRT use (n=82), num-
ber of children (n=5), and APOE geno-
type (n=281). Finally, we examined the
relationship between reproductive pe-
riod in women with and without at least
1 APOE e4 allele.
RESULTS
Of the 3601 women, 577 (16%) died
during follow-up. The mean (SD) re-
productive period of the women who
died during follow-up was 34.7 (5.1)
years and that of those who remained
alive was 35.1 (5.2) years (P=.12 us-
ing t test). Logistic regression analy-
ses with adjustments for age and edu-
cation showed that in women with
natural menopause, reproductive years
were not significantly associated with
risk of death (relative risk per year in-
crease, 1.00; 95% confidence interval
[CI], 0.97-1.02). Also, women who had
artificial menopause did not have a
higher risk of death compared with
women who had natural menopause
(relative risk, 1.01; 95% CI, 0.79-1.29).
One participant with missing data on
education developed dementia, as did 83
with missing data on alcohol intake, 31
with missing data on BMI, 13 with miss-
ing data on HRT use, and 22 with miss-
ing data on APOE genotype. None of the
women with missing data on number of
children developed dementia. Women
with missing data on BMI, APOE geno-
type, or alcohol intake were older and,
for alcohol intake, had a lower level of
education. When adjusted for age, other
characteristics of those with missing data
did not differ from women with com-
plete data. Quartile of reproductive pe-
riod was not associated with missing data
on either variable when adjusted for age.
The mean (SD) reproductive period
in women with natural menopause was
35.9 (4.6) years. TABLE 1 presents the
demographics of the study population
by quartile of reproductive period in
women with natural and artificial meno-
pause. Age was inversely related to num-
ber of reproductive years. Women with
more than 39 reproductive years (high-
est quartile) on average had higher lev-
els of education, had a higher BMI, and
were more often never smokers than
women with fewer than 34 reproduc-
tive years (lowest quartile). Alcohol in-
take, number of children, use of HRT,
and APOE genotype were similar across
Table 1. Baseline Characteristics by Quartile of Reproductive Years in Women With Natural
and Artificial Menopause
Characteristics
Reproductive Period, y (Range, 15-49 y)
Artificial
Menopause
(n = 865)
,34
(n = 687)
34-36
(n = 672)
37-39
(n = 794)
.39
(n = 583)
Reproductive period, mean (SD), y 29.7 (3.2) 35.1 (0.8) 37.9 (0.8) 41.6 (1.7) 32.1 (5.8)
Age at menopause, mean (SD), y 44.1 (3.5) 49.2 (1.8) 51.3 (1.6) 54.2 (1.9) 45.7 (5.6)
Age at menarche, mean (SD), y 14.4 (2.0) 14.1 (1.7) 13.4 (1.5) 12.6 (1.4) 13.5 (1.8)
Age at baseline, mean (SD), y 71.7 (9.5) 70.3 (9.4) 70.0 (9.5) 68.7 (8.8) 68.3 (8.3)
Level of education, %
Completed primary education 34.9 28.7 28.8 24.1 29.7
Higher education 65.1 71.3 71.2 75.9 70.3
Smoking status, %
Never 51.1 55.4 54.3 56.8 51.7
Former 28.5 25.6 27.3 27.6 30.5
Current 20.4 19.0 18.4 15.6 17.8
Alcohol intake, mean (SD), g/d 5.8 (8.5) 6.1 (9.2) 5.8 (8.3) 6.5 (9.3) 6.1 (9.8)
Body mass index, mean (SD), kg/m2 26.5 (4.0) 26.7 (4.1) 26.7 (4.1) 27.4 (4.0) 26.9 (3.8)
No. of children, mean (SD) 2.0 (1.7) 2.1 (1.7) 2.1 (1.8) 2.2 (1.7) 2.2 (1.7)
Use of hormone
replacement therapy, %
Never 90.5 91.7 90.6 91.4 84.9
Ever 9.5 8.3 9.4 8.6 15.1
Apolipoprotein E genotype, %
No e4 allele 70.3 74.7 73.0 71.3 73.3
At least 1 e4 allele 29.7 25.3 27.0 28.7 26.7
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strata of reproductive period in women
with natural menopause. Women with
artificial menopause were younger, had
a younger age at menopause, and were
more likely to have used HRT than
women with natural menopause.
Women who were excluded from the
analytic sample because of incomplete
data on reproductive period or type of
menopause were older and less likely to
have used HRT than women with com-
plete data. The groups did not differ with
respect to other covariates.
During 21046 person-years of fol-
low-up (median follow-up, 6.3 years;
range, 0.0-9.4 years), 199 women were
diagnosed as having dementia (159 with
AD). Of the 3601 women in the study
sample, 13 (0.4%) were lost to follow-
up. The FIGURE shows crude age-
specific incidence rates of dementia per
1000 person-years by quartile of repro-
ductive period and type of menopause.
Incidence rates among women younger
than 70 years and older than 94 years are
not presented because there were too few
dementia cases in these women. Inci-
dence rates were somewhat higher in
women with a longer reproductive pe-
riod compared with those with the short-
est period until age 85 years, after which
nopattern in incidence rates couldbedis-
cerned(Figure).The incidence rateswere
significantly higher only for the highest
vs lowest quartiles when adjusted for age
only (TABLE 2). However, in Cox pro-
portional hazards models adjusted for
age, education, smoking status, alcohol
intake, BMI, HRT use, number of chil-
dren, and APOE genotype, risk of de-
mentiawasconsistentlyhigher inwomen
with a longer reproductive period com-
pared with women with a shorter repro-
ductive period. Risk of dementia in
women with 34 to 36 reproductive years
was 1.56 (95% CI, 1.00-2.43) times
higher than in women with less than 34
reproductive years; in women with 37 to
39 reproductive years, this risk was 1.64
(95% CI, 1.07-2.53) times higher, and
in women with more than 39 reproduc-
tive years, it was 1.78 (95% CI, 1.12-
2.84) times higher than in women with
less than 34 reproductive years (Table 2).
When reproductive period was entered
asacontinuousvariable, theadjusted rate
ratio (RR) per year increase in women
with a natural menopause was 1.04 (95%
CI, 1.01-1.08). For AD, the risks showed
a similar but not statistically significant
pattern of higher risk with longer repro-
ductive period (Table 2).
Women with artificial menopause did
not have a significantly increased risk of
dementia or AD compared with women
with less than 34 reproductive years
(Table 2). When we compared women
with artificial menopause with all
women with natural menopause (re-
gardless of their reproductive period),
again, their risk of dementia was not in-
creased (adjusted RR, 0.81; 95% CI,
0.55-1.19). When we examined the re-
lationship in women who reported never
using oral contraceptives or HRT (167
incident dementia cases), the adjusted
RRs associated with dementia for the sec-
ond, third, and fourth quartiles of re-
productive period relative to the low-
est quartile were 1.76 (95% CI, 1.10-
2.82), 1.74 (95% CI, 1.10-2.76), and
1.52 (95% CI, 0.90-2.58), respectively.
Among women who never used oral
contraceptives or HRT, women with ar-
tificial menopause did not have a sig-
nificantly increased risk of dementia
compared with women with less than 34
reproductive years (RR, 1.31; 95% CI,
0.77-2.21). To determine whether the
relationship between reproductive pe-
riod and risk of dementia may have been
influenced by women who were diag-
nosed as having dementia after a rela-
tively short period, we performed the
analyses without the first 2 years of fol-
low-up. In these analyses, the observed
relationship remained unchanged. The
adjusted RR associated with dementia for
the highest quartile of reproductive pe-
riod compared with the lowest quartile
was 2.74 (95% CI, 1.50-4.99); these RRs
for the second and third quartiles were
1.59 (95% CI, 0.84-3.01) and 2.06 (95%
CI, 1.14-3.72), respectively.
TABLE 3 presents the relationship be-
tween reproductive period and AD across
strata of APOE genotype. Number of re-
productive years was not clearly associ-
ated with risk of AD and dementia in
women without an APOE e4 allele. How-
ever, women with at least 1 APOE e4 al-
lele had a higher risk of dementia and AD
if they had had a longer reproductive pe-
riod. For dementia, in the group with at
least 1 APOE e4 allele, the adjusted RR
Figure. Crude Age-Specific Incidence Rates
of Dementia by Quartile of Reproductive
Period and Type of Menopause
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Reproductive period was defined as age at natural
menopause minus age at menarche.
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in the highest quartile compared with the
lowest quartile was 4.20 (95% CI, 1.97-
8.92), in the third quartile it was 1.93
(95% CI, 0.87-4.31), and in the second
quartile it was 2.43 (95% CI, 1.10-
5.36), whereas in the group with no
APOE e4 alleles, these RRs were 1.10
(95% CI, 0.54-2.26), 1.29 (95% CI, 0.71-
2.34), and 1.29 (95% CI, 0.71-2.36), re-
spectively. The interaction term testing
statistical interaction was significant for
dementia (P = .02) but not for AD
(P=.07). When reproductive period was
entered as a continuous variable, the ad-
justed RR per year of increase in women
with natural menopause was 1.08 (95%
CI, 1.02-1.15) for dementia and 1.09
(95% CI, 1.02-1.16) for AD in the group
with at least 1 APOE e4 allele, whereas
in the group without an APOE e4 allele,
this RR was 1.02 (95% CI, 0.97-1.07) for
dementia and 1.00 (95% CI, 0.95-1.06)
for AD. The P values for tests of statis-
tical interaction for dementia and AD
were .07 and .02, respectively.
TABLE 4 presents the RRs for the as-
sociation of age at menarche and age at
natural menopause with incident de-
mentia and AD. Age at menarche was not
significantly associated with risk of de-
mentia and AD, whereas age at natural
menopause reflected the results of the
analyses using reproductive period.
COMMENT
In this population-based study, a longer
reproductive period was associated with
Table 2. Rate Ratios of the Relationship Between Reproductive Period or Artificial Menopause and Incident Dementia and Alzheimer Disease
Dementia
(n = 199)
Alzheimer Disease
(n = 159)
No. of
Cases
Age-Adjusted
Rate Ratio (95% CI)
Adjusted Rate
Ratio (95% CI)*
No. of
Cases
Age-Adjusted
Rate Ratio (95% CI)
Adjusted Rate
Ratio (95% CI)*
Reproductive period, y
,34 37 Referent Referent 34 Referent Referent
34-36 44 1.43 (0.92-2.22) 1.56 (1.00-2.43) 34 1.23 (0.76-1.98) 1.32 (0.81-2.14)
37-39 50 1.46 (0.95-2.25) 1.64 (1.07-2.53) 39 1.27 (0.80-2.02) 1.41 (0.88-2.25)
.39 36 1.64 (1.03-2.60) 1.78 (1.12-2.84) 28 1.40 (0.84-2.31) 1.51 (0.91-2.50)
Artificial menopause 32 1.09 (0.67-1.75) 1.17 (0.72-1.89) 24 0.91 (0.53-1.54) 0.95 (0.56-1.63)
Per y increase in reproductive
period†
167 1.03 (1.00-1.07) 1.04 (1.01-1.08) 135 1.03 (0.99-1.07) 1.03 (1.00-1.07)
*Data are adjusted for age, education, smoking status, alcohol intake, body mass index, use of hormone replacement therapy, number of children, and apolipoprotein E genotype.
CI indicates confidence interval.
†Among women with natural menopause.
Table 3. Rate Ratios for AD Associated With Reproductive Period According to APOE Genotype*
No APOE e4 Allele At Least 1 APOE e4 Allele
No. of
AD Cases
Age-Adjusted
Rate Ratio (95% CI)
Adjusted Rate
Ratio (95% CI)†
No. of
AD Cases
Age-Adjusted
Rate Ratio (95% CI)
Adjusted Rate
Ratio (95% CI)†
Reproductive period, y
,34 20 Referent Referent 10 Referent Referent
34-36 19 1.17 (0.62-2.20) 1.19 (0.63-2.25) 11 1.78 (0.73-4.35) 1.62 (0.65-4.03)
37-39 19 1.02 (0.54-1.93) 1.13 (0.59-2.13) 13 1.67 (0.72-3.89) 1.74 (0.74-4.09)
.39 9 0.87 (0.39-1.91) 0.87 (0.39-1.91) 17 3.16 (1.42-7.05) 3.42 (1.51-7.75)
Artificial menopause 16 0.99 (0.51-1.94) 1.03 (0.53-2.03) 8 1.16 (0.45-2.99) 0.92 (0.34-2.47)
Per y increase in reproductive period‡ 67 1.00 (0.95-1.05) 1.00 (0.95-1.06) 51 1.08 (1.01-1.15) 1.09 (1.02-1.16)
*AD indicates Alzheimer disease; APOE, apolipoprotein E gene; and CI, confidence interval. Seventeen AD cases had missing data on APOE genotype.
†Data are adjusted for age, education, smoking status, alcohol intake, body mass index, use of hormone replacement therapy, and number of children.
‡Among women with natural menopause.
Table 4. Adjusted Rate Ratios for Association of Ages at Menarche and Natural Menopause
With Incident Dementia and Alzheimer Disease
Dementia
(n = 199)
Alzheimer Disease
(n = 159)
No. of
Cases
Rate Ratio
(95% CI)*
No. of
Cases
Rate Ratio
(95% CI)*
Age at menarche, y
.14 61 Referent 52 Referent
14 37 0.89 (0.57-1.29) 28 0.76 (0.48-1.21)
13 40 1.00 (0.67-1.50) 30 0.89 (0.56-1.40)
#12 61 1.18 (0.82-1.70) 49 1.15 (0.77-1.72)
Age at menopause, y
,48 32 Referent 30 Referent
48-49 23 1.24 (0.72-2.15) 16 0.90 (0.48-1.68)
50-52 75 1.95 (1.28-2.96) 60 1.64 (1.05-2.56)
.52 37 1.78 (1.11-2.88) 29 1.47 (0.88-2.46)
*Data are adjusted for age, education, smoking status, alcohol intake, body mass index, hormone replacement therapy,
number of children, and apolipoprotein E genotype. Data adjusted for age only did not differ significantly (available
on request from author). CI indicates confidence interval.
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a higher risk of dementia in women with
natural menopause, after adjustment for
multiple confounding variables. This risk
was found in women with at least 1
APOE e4 allele, whereas women with-
out APOE e4 alleles did not have an as-
sociation between reproductive period
and dementia. Insofar as reproductive pe-
riod is a marker of long-term exposure
to endogenous estrogen, these findings
do not support the hypothesis that high
estrogen levels reduce risk of dementia.
Several methodological issues should
be considered. First, misclassification
may have occurred as a result of errors
in recall with respect to age at menar-
che and menopause. In particular, age
at menopause may be difficult to re-
member because it is not an event that
occurs at 1 point in time. We tried to
avoid recall bias as much as possible by
using consistent reports at baseline and
the first follow-up measurement (for
women who were still available at the
first follow-up interview). Still, it is pos-
sible that, in particular, women in the
highest age range and those who were
diagnosed as having dementia after a
relatively short period had difficulty re-
membering their age at menopause.
However, when we excluded all women
who were diagnosed as having demen-
tia within 2 years of follow-up, the point
estimates were higher than the risk es-
timates based on the entire follow-up pe-
riod. Thus, possible misclassification re-
sulted in a weakening of the association.
Second, we had no data on number of
pregnancies that did not end in a live
birth, lactation, or regularity of men-
strual cycles, nor do we know to what
extent use of other hormones (eg, pro-
gesterone) may have influenced the ob-
served relationship. Finally, due to the
small number of cases, we could not ex-
amine the relationship between repro-
ductive period and vascular dementia.
This study is, to our knowledge, the
first to examine the long-term effects
of reproductive period on risk of de-
veloping dementia and AD. The
strengths of this study are its size, its
prospective design, and its population-
based character. Furthermore, we were
able to obtain complete follow-up with
respect to dementia diagnoses. In this
respect, selection bias cannot explain
the results. However, selection could
have occurred prior to study entry.
Women with a very early natural meno-
pause may have a higher risk of coro-
nary heart disease2 and death.34-36 As a
result, women with an early meno-
pause who survived and entered the co-
hort may have been healthier than
women with a later menopause and,
thus, at lower risk of dementia. Women
with a shorter reproductive period (and,
thus, a younger age at menopause)
were, on average, older at baseline than
women with a longer reproductive pe-
riod. Although this could indicate
longer survival as a result of better
health status, their higher age at base-
line would have made them at higher
risk of dementia. Alternatively, this age
difference may reflect a cohort effect in
that women in a younger birth cohort
tend to have a later age at menopause
and an earlier age at menarche. Fi-
nally, we did not observe a significant
relationship between reproductive pe-
riod and survival in the women who did
enter our cohort. Thus, it is unlikely
that selective survival could explain the
findings of this study.
Although a number of studies have
found protective effects of exogenous
estrogen on risk of dementia11-16 and
cognitive functions,37-40 others have not
found a relationship,41,42 and some have
even suggested that estrogen may have
negative effects.20,21,43-45 Recently, a large,
randomized, controlled clinical trial of
women with mild-to-moderate AD did
not find a slower rate of disease pro-
gression in women treated with estro-
gen compared with placebo.43 On 1 out-
come measure (the Clinical Dementia
Rating Scale), the estrogen group wors-
ened even more rapidly than the pla-
cebo group. In another randomized
controlled clinical trial of patients with
AD, the estrogen replacement therapy
group showed somewhat greater de-
cline on the Alzheimer’s Disease As-
sessment Scale—Cognitive compared
with the control group.44 More re-
cently, the Cardiovascular Health Study
reported that women who used estro-
gen replacement therapy had greater
ventricular enlargement and larger bi-
frontal distance than nonusers, sug-
gesting more cerebral atrophy.45 With
respect to endogenous estrogen, some
studies have observed that high levels
of estradiol and estrone were associ-
ated with lower scores on 1 of several
cognitive tasks.21,20
It is possible that factors associated
with reproductive period other than en-
dogenous estrogens increase risk of de-
mentia. Although we used reproduc-
tive period as an indirect indicator of
exposure to endogenous estrogens,
many other factors are involved
throughout the reproductive period that
may influence estrogen levels, includ-
ing number of pregnancies (with or
without live births), lactation, regular-
ity of menstrual cycles, and use of oral
contraceptives. Although we took some
of these factors into account in the
analyses, we did not have information
on other factors. This may have lim-
ited the validity of reproductive pe-
riod as an indicator of long-term expo-
sure to endogenous estrogens. It is also
possible that another unknown factor
interacts with hormonal influences or
that reproductive period is an indica-
tor of another risk factor for demen-
tia. The increased risk with longer re-
productive period was most significant
in overall dementia (relative to AD). It
may be possible that vascular factors in-
teract with hormonal factors in increas-
ing risk of dementia. Unfortunately,
there were too few cases of vascular de-
mentia to explore this possibility.
The risk of dementia associated with
reproductive period was higher in
women with at least 1 APOE e4 allele,
while no association was observed in
women without an APOE e4 allele. Es-
trogen and APOE may interact at sev-
eral levels. Estrogen modulates the ex-
pression of APOE in mice.46 Women
with an APOE e4 allele may have a
higher incidence of AD than men with
an APOE e4 allele.47,48 A recent study
found that estrogen replacement
therapy was less effective in women
with an APOE e4 allele.49 An increased
risk of dementia in women with both
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a longer reproductive period and an
APOE e4 allele has not been reported
before, however.
In conclusion, this population-
based study does not support the
hypothesis that a longer reproductive
period in women, as an indicator of
long-term exposure to endogenous es-
trogen, reduces risk of dementia and
AD. Further research is needed on the
possible differential effects of endoge-
nous vs exogenous estrogen and the
short- vs long-term effects of estrogen
on risk of dementia.
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